CoChat

Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets

Robillard, Nelly, Wuillème, Soraya, Moreau, Philippe, Béné, Marie C. · 2014 · Frontiers in Immunology
Cited by 82

The DOI matches its Crossref record.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2014.00137

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 25

  1. Tatsas, 2010, Monitoring residual myeloma: high-resolution serum/urine electrophoresis or marrow biopsy with immunohistochemical analysis?, Am J Clin Pathol, 134, 139, 10.1309/AJCP69TCAVDGSCWI · DOI
  2. Guikema, 2004, Heterogeneity in the multiple myeloma tumor clone, Leuk Lymphoma, 45, 857, 10.1080/10428190310001593201 · DOI
  3. Bataille, 2006, The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy, Haematologica, 91, 1234
  4. Raja, 2010, Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders, Br J Haematol, 149, 334, 10.1111/j.1365-2141.2010.08121.x · DOI
  5. Cannizzo, 2010, Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology, Cytometry B Clin Cytom, 78, 231, 10.1002/cyto.b.20517 · DOI
  6. Rawstron, 2006, Immunophenotyping of plasma cells, Curr Protoc Cytom, 6, 6.23, 10.1002/0471142956.cy0623s36 · doi:10.1002/0471142956.cy0623s36
  7. Robillard, 2013, A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma, Blood Cancer J, 3, e134, 10.1038/bcj.2013.33 · doi:10.1038/bcj.2013.33
  8. Peceliunas, 2011, Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors, Cytometry B Clin Cytom, 80, 318, 10.1002/cyto.b.20601 · DOI
  9. Medina, 2002, The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression, Blood, 99, 2154, 10.1182/blood.V99.6.2154 · DOI · Paper page
  10. Mateo, 2005, Genetic abnormalities and patterns of antigenic expression in multiple myeloma, Clin Cancer Res, 11, 3661, 10.1158/1078-0432.CCR-04-1489 · doi:10.1158/1078-0432.ccr-04-1489
  11. Magrangeas, 2013, Minor clone provides a reservoir for relapse in multiple myeloma, Leukemia, 27, 473, 10.1038/leu.2012.226 · DOI · Paper page
  12. Arnoulet, 2010, Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: a reference document based on a systematic approach by the GTLLF and GEIL, Cytometry B Clin Cytom, 78, 4, 10.1002/cyto.b.20484 · doi:10.1002/cyto.b.20484
  13. Moreau, 2004, Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma, Haematologica, 89, 547
  14. Liu, 2012, Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma, J Clin Pathol, 65, 823, 10.1136/jclinpath-2012-200881 · DOI
  15. Kumar, 2010, Immunophenotyping in multiple myeloma and related plasma cell disorders, Best Pract Res Clin Haematol, 23, 433, 10.1016/j.beha.2010.09.002 · DOI
  16. Paiva, 2010, Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders, Cytometry B Clin Cytom, 78, 239, 10.1002/cyto.b.20512 · DOI · Paper page
  17. Ocqueteau, 1996, Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells, Br J Haematol, 95, 489, 10.1111/j.1365-2141.1996.tb08993.x · DOI
  18. Montero, 2008, Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity, Haematologica, 93, 851, 10.3324/haematol.12171 · DOI
  19. Schmidt-Hieber, 2011, CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features, Haematologica, 96, 328, 10.3324/haematol.2010.031872 · doi:10.3324/haematol.2010.031872
  20. Mateo, 2008, Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy, J Clin Oncol, 26, 2737, 10.1200/JCO.2007.15.4120 · DOI · Paper page
  21. Cannizzo, 2012, The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model, Am J Clin Pathol, 137, 377, 10.1309/AJCP63TOCFNAMDMS · DOI
  22. Bataille, 2008, CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis, Leuk Res, 32, 379, 10.1016/j.leukres.2007.07.016 · DOI
  23. Grigoriadis, 2012, Is CD20 positive plasma cell myeloma a unique clinicopathological entity? A study of 40 cases and review of the literature, Pathology, 44, 552, 10.1097/PAT.0b013e3283583f5d · DOI
  24. Moreau, 2007, Rituximab in CD20 positive multiple myeloma, Leukemia, 21, 835, 10.1038/sj.leu.2404558 · DOI
  25. Robillard, 2005, CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target, Leukemia, 19, 2021, 10.1038/sj.leu.2403948 · DOI

Cited by

See all 82

Metadata

Authors
Robillard, N., Wuillème, S., Moreau, P., & Béné, M. C.
Venue
Frontiers in Immunology
Published
2014-03-31
Volume
5
ISSN
1664-3224
Cited by
82
References
0

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets. https://app.cochat.ai/papers/10.3389/fimmu.2014.00137
The paper
Robillard, N., Wuillème, S., Moreau, P., & Béné, M. C. (2014). Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2014.00137

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.